22157.jpg
Outlook on the Global Refractory Angina Industry to 2030 - 11-Year Forecast of Refractory Angina Epidemiology
September 09, 2020 06:53 ET | Research and Markets
Dublin, Sept. 09, 2020 (GLOBE NEWSWIRE) -- The "Refractory Angina (RA) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth...
Avinger Inc. Logo
Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device
December 13, 2018 07:00 ET | Avinger, Inc.
REDWOOD CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that...
Avinger Inc. Logo
Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018
May 04, 2018 08:00 ET | Avinger, Inc.
REDWOOD CITY, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will...
Avinger Inc. Logo
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018
April 30, 2018 08:30 ET | Avinger, Inc.
REDWOOD CITY, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next...
Avinger Inc. Logo
Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
March 29, 2018 09:00 ET | Avinger, Inc.
REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Arne...